Table 5.

Patients With History of Reaction to COVID-19 Vaccine and PEG Chemically Related Products

Variables	Reaction to COVID-19 vaccineN = 40 (%)	Reaction to PEG chemically related compoundsN = 4 (%)
Brighton criteria classificationa
1	4 (10%)	1 (25%)
2	11 (27.5%)	2 (50%)
3	9 (22.5%)	1 (25%)
4	3 (7.5%)	0
5	13 (32.5%)	0
NIAID and FAAN criteriab	15 (37.5%)	3 (75%)
Immediate reactionc	27 (67.5%)	4 (100%)
Delayed reactiond	13 (32.5%)	0
Positive SPT Negative SPT	3 (7.5%) 37 (92.5%)	2 (50%) 2 (50%)
Method of second dose of vaccine being administered
-Single full dose	16 (40%)	2 (50%)
-Two divided doses	18 (45%)	2 (50%)
-Graded doses	6 (15%)	0
Reacted to second dose of the COVID-19 vaccine14
-Single full dose	0	0
-Two divided doses	0	0
-Graded dosing	2 (5%)	0

Abbreviations: COVID-19, coronavirus disease 2019; FAAN, Food Allergy and Anaphylaxis Network; NIAID, National Institute of Allergy and Infectious Diseases; PEG, polyethylene glycol; SPT, skin prick test.

^aThe Brighton Collaboration case definition uses combinations of symptoms to define levels of diagnostic certainty. Brighton level 1 represents the highest level of diagnostic certainty that a reported case represents anaphylaxis; levels 2 and 3 are successively lower levels of diagnostic certainty; level 4 is a case reported as anaphylaxis but that does not meet the Brighton Collaboration case definition; and level 5 is a case that was neither reported as anaphylaxis nor meets the case definition. This study considered Brighton level 1 or 2 anaphylaxis cases.

^bNIAID/FAAN clinical criteria for the diagnosis of anaphylaxis must meet 1 of the following criteria: (1) acute onset with involvement of skin or mucosal tissue and either (a) respiratory compromise or (b) reduced blood pressure or associated symptoms of end-organ dysfunction; (2) 2 or more of the following occur after exposure to a likely allergen for that patient: (a) involvement of skin or mucosal tissue, (b) respiratory compromise, (c) reduced blood pressure or associated symptoms, or (d) persistent gastrointestinal symptoms; and (3) reduced blood pressure after exposure to a known allergen for that patient.

^cImmediate reaction: within the first hour after receiving the vaccine, the patients reported urticaria angioedema and/or throat tightness and/or bronchospasm and/or drowsiness.

^dDelayed reaction: after 1 h from receiving the vaccine the patient reported urticaria angioedema and/or maculopapular rash.